Abstract |
In this study we investigated the pattern of T lymphocyte changes in 16 adult patients with acute myeloid leukaemia (8), non-Hodgkin's lymphoma (4) and Hodgkin's disease (4) treated with continuous infusion of recombinant interleukin-2 (rIL-2). Effects indicative of lymphocyte activation occurred even prior to any rIL-2 therapy in these patients, being most prominent in patients with active diseases. Following each course of cytokine therapy, there were further changes in these parameters. Significant rebound lymphocytoses occurred with a concomitant increase in the cytotoxic functions and induction of the cytotoxicity-linked cytoplasmic serine esterase. Hence, both the natural killer and lectin-dependent cellular cytotoxicity activities were up-regulated. There were also increases in the serum sIL-2 receptor, sCD4 and sCD8 levels. More CD3+ lymphocytes, especially cells bearing CD4, were also recruited to the pool of potential effector cells, as demonstrated by the greater proportion of cells expressing the cytoplasmic serine esterase.
|
Authors | S H Lim, C Worman, A Jewell, C Tsakona, F J Giles, A Goldstone |
Journal | Cancer immunology, immunotherapy : CII
(Cancer Immunol Immunother)
Vol. 33
Issue 2
Pg. 133-7
( 1991)
ISSN: 0340-7004 [Print] Germany |
PMID | 2036661
(Publication Type: Journal Article)
|
Chemical References |
- Antigens, CD
- Interleukin-2
- Receptors, Interleukin-2
- Recombinant Proteins
- Esterases
- serine esterase
|
Topics |
- Adult
- Antigens, CD
(analysis)
- Cytotoxicity, Immunologic
- Enzyme Induction
- Esterases
(biosynthesis)
- Hodgkin Disease
(immunology, therapy)
- Humans
- Interleukin-2
(pharmacology, therapeutic use)
- Leukemia, Myeloid, Acute
(immunology, therapy)
- Lymphocyte Activation
- Lymphoma, Non-Hodgkin
(immunology, therapy)
- Receptors, Interleukin-2
(analysis)
- Recombinant Proteins
(pharmacology, therapeutic use)
|